NL-OMON39212尚未招募不适用
The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate risk prostate carcinoma (NEO-ONE) - NHT influence on PSA and testosterone after brachytherapy (NEO-ONE)
TweeSteden ziekenhuis0 个研究点目标入组 400 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •These are the inclusioncriteria:
- •Patients with low and intermediate risk prostate cancer (according to Dutch guidelines)
- •prostate volume between 35 and 55 cc
- •a life expectancy of at least 10 years
- •written informed consent
排除标准
- •These are the exclusion criteria:
- •Contra-indication for BT
- •use of hormone suppressive therapy in the past or surgical castration.
- •use of 5 alfa reductase in the last 6 months
- •use of estrogens
- •cognitive impairments
- •negative decision for study participation by the hospitals* urology-radiotherapy meeting
- •kidney or liver dysfunction
- •history of myocardial infarction with present symptoms or CAD-induced heart failure
研究者
相似试验
进行中（未招募）
不适用
The effects of pretreatment with androgen blocking hormones before brachytherapy for prostate cancer on the course of PSA and testosterone after treatmentocalized prostate cancerMedDRA version: 14.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004749-41-NLTweeSteden hospital
进行中（未招募）
1 期
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in SituEUCTR2020-003575-18-FRINSTITUT DE CANCEROLOGIE DE L'OUEST262
已完成
2 期
Effect of hormonal therapy versus no treatment on testicular histopathology and fertility in patients with non-obstructive azoospermianon-obstructive azoospermia.Male infertilityIRCT201612069014N137Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences28
招募中
Unknown
Retrospective study of the efficacy of hormonal therapy for advanced or recurrent low-grade endometrial stromal sarcomaunresectable advanced or recurrent low-grade endometrial stromal sarcomaJPRN-UMIN000050780Shizuoka Cancer Center40
进行中（未招募）
不适用
Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hormonal therapyFemale patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapyMedDRA version: 14.1Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-000155-16-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI